Thymosin Alpha-1 Shifts Hepatitis C Patients' Immune Cells Toward Virus-Fighting Mode
Thymosin alpha-1 combined with interferon shifted the Th1/Th2 cytokine balance in hepatitis C patients toward Th1 (virus-fighting) dominance, while interferon alone had limited effect on this balance.
Quick Facts
What This Study Found
Thymosin alpha-1 + IFN-alpha shifted Th1/Th2 balance toward Th1 dominance (increased IFN-γ/IL-2, decreased IL-4/IL-10) in HCV patient PBMCs, while IFN-alpha alone produced only partial Th1 enhancement.
Key Numbers
How They Did This
In-vitro study using peripheral blood mononuclear cells from chronic hepatitis C patients. Thymosin alpha-1, IFN-alpha, and their combination tested for Th1 and Th2 cytokine production.
Why This Research Matters
Hepatitis C persistence is linked to Th2-dominant immune profiles. A therapeutic that shifts this balance toward Th1 could help achieve viral clearance, explaining thymosin alpha-1's clinical benefit.
The Bigger Picture
Many chronic infections persist because the immune system is stuck in the wrong mode (Th2). Thymosin alpha-1's ability to repolarize immunity toward Th1 has implications beyond hepatitis for any infection requiring cellular immunity.
What This Study Doesn't Tell Us
In-vitro study; immune cell behavior in culture may differ from in vivo. Patient heterogeneity. The degree of Th1 shift needed for clinical benefit is uncertain.
Questions This Raises
- ?Does the Th1 shift predict clinical response to thymosin alpha-1 therapy?
- ?Could thymosin alpha-1 benefit other chronic viral infections with Th2 dominance?
- ?Is the Th1 shift sustained after treatment stops?
Trust & Context
- Key Stat:
- Immune mode shift Combined thymosin alpha-1 + IFN shifted immune balance from Th2 (infection-permissive) to Th1 (virus-fighting) — the key to clearing hepatitis C
- Evidence Grade:
- Preliminary in-vitro evidence using patient cells, providing a mechanistic explanation for thymosin alpha-1's clinical benefit in hepatitis C.
- Study Age:
- Published in 2001. While HCV is now treated with direct-acting antivirals, thymosin alpha-1's Th1-promoting mechanism remains relevant for other chronic infections.
- Original Title:
- In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C.
- Published In:
- Journal of viral hepatitis, 8(3), 194-201 (2001)
- Authors:
- Andreone, P(2), Cursaro, C(2), Gramenzi, A(2), Margotti, M, Ferri, E, Talarico, S, Biselli, M, Felline, F, Tuthill, C, Martins, E, Gasbarrini, G, Bernardi, M
- Database ID:
- RPEP-00644
Evidence Hierarchy
Frequently Asked Questions
What is the Th1/Th2 balance?
The immune system has two modes: Th1 fights viruses and intracellular infections, while Th2 fights parasites and allergies. In chronic hepatitis C, the immune system is stuck in Th2 mode, allowing the virus to persist. Thymosin alpha-1 helps switch it back to Th1.
Why does this matter if hepatitis C is now curable?
The Th1-promoting mechanism applies to many chronic infections beyond HCV. Any infection where the immune system is stuck in the wrong mode could potentially benefit from thymosin alpha-1's immune repolarization.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00644APA
Andreone, P; Cursaro, C; Gramenzi, A; Margotti, M; Ferri, E; Talarico, S; Biselli, M; Felline, F; Tuthill, C; Martins, E; Gasbarrini, G; Bernardi, M. (2001). In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C.. Journal of viral hepatitis, 8(3), 194-201.
MLA
Andreone, P, et al. "In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C.." Journal of viral hepatitis, 2001.
RethinkPeptides
RethinkPeptides Research Database. "In vitro effect of thymosin-alpha1 and interferon-alpha on T..." RPEP-00644. Retrieved from https://rethinkpeptides.com/research/andreone-2001-in-vitro-effect-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.